Is EUDA Health Holdings Ltd. overvalued or undervalued?

As of 10 May 2023, the valuation grade for EUDA Health Holdings Ltd. has moved from does not qualify to risky. The company appears to be overvalued given its significant negative ratios, including a Price to Book Value of -50.06 and an EV to EBITDA of -53.53. The current price of $3.58 is notably higher than its 52-week low of $2.83, but the overall financial metrics suggest a concerning outlook.
In comparison to its peers, EUDA Health Holdings Ltd. has a P/E ratio of -55.03, while GeneDx Holdings Corp. shows a P/E of -63.58 and Personalis, Inc. has a P/E of -6.55. This indicates that EUDA is not only underperforming relative to its peers but also struggling with negative returns on capital. The company's year-to-date return of -20% starkly contrasts with the S&P 500's gain of 2.44%, reinforcing the notion that EUDA is overvalued in its current state.